MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2)
Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of MK6186 and the change from baseline
in plasma HIV-1 RNA after seven consecutive days of dosing.